Cargando…
Epicatechin oligomers longer than trimers have anti-cancer activities, but not the catechin counterparts
Since procyanidins (oligomeric catechin or epicatechin) were reported to exhibit health benefits, much attention has been paid to the synthesis of these compounds, especially those that are longer than trimers. In the present study, syntheses of cinnamtannin A3 (epicatechin pentamer), A4 (epicatechi...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5552761/ https://www.ncbi.nlm.nih.gov/pubmed/28798415 http://dx.doi.org/10.1038/s41598-017-08059-x |
_version_ | 1783256511823216640 |
---|---|
author | Takanashi, Kohki Suda, Manato Matsumoto, Kiriko Ishihara, Chisato Toda, Kazuya Kawaguchi, Koichiro Senga, Shogo Kobayashi, Narumi Ichikawa, Mikihiro Katoh, Miyuki Hattori, Yasunao Kawahara, Sei-ichi Umezawa, Koji Fujii, Hiroshi Makabe, Hidefumi |
author_facet | Takanashi, Kohki Suda, Manato Matsumoto, Kiriko Ishihara, Chisato Toda, Kazuya Kawaguchi, Koichiro Senga, Shogo Kobayashi, Narumi Ichikawa, Mikihiro Katoh, Miyuki Hattori, Yasunao Kawahara, Sei-ichi Umezawa, Koji Fujii, Hiroshi Makabe, Hidefumi |
author_sort | Takanashi, Kohki |
collection | PubMed |
description | Since procyanidins (oligomeric catechin or epicatechin) were reported to exhibit health benefits, much attention has been paid to the synthesis of these compounds, especially those that are longer than trimers. In the present study, syntheses of cinnamtannin A3 (epicatechin pentamer), A4 (epicatechin hexamer), catechin tetramer, pentamer, arecatannin A2 (epicatechin-epicatechin-epicatechin-catechin) and A3 (epicatechin-epicatechin-epicatechin-epicatechin-catechin) were achieved. The key reaction was a Lewis acid mediated equimolar condensation. The antitumor effects of these synthesized compounds against a human prostate cancer cell line (PC-3) were investigated. Among the tested compounds, cinnamtannin A3, A4 and arecatannin A3, which possess epicatechin oligomers longer than tetramers as the basic scaffold, showed significant activities for suppression of cell growth, invasion and FABP5 (fatty acid-binding protein 5) gene expression. Effects on cell cycle distribution showed that cell cycle arrest in the G2 phase was induced. Furthermore, these epicatechin oligomers suppressed significantly the expression of the cancer-promoting gene, FABP5, which is related to cell proliferation and metastasis in various cancer cells. Interestingly, the suppressive activities were associated with the degree of oligomerization of epicatechin. Thus, synthetic studies clearly demonstrate that epicatechin oligomers longer than trimers have significant anti-tumorigenic activities, but not the catechin counterparts. |
format | Online Article Text |
id | pubmed-5552761 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-55527612017-08-14 Epicatechin oligomers longer than trimers have anti-cancer activities, but not the catechin counterparts Takanashi, Kohki Suda, Manato Matsumoto, Kiriko Ishihara, Chisato Toda, Kazuya Kawaguchi, Koichiro Senga, Shogo Kobayashi, Narumi Ichikawa, Mikihiro Katoh, Miyuki Hattori, Yasunao Kawahara, Sei-ichi Umezawa, Koji Fujii, Hiroshi Makabe, Hidefumi Sci Rep Article Since procyanidins (oligomeric catechin or epicatechin) were reported to exhibit health benefits, much attention has been paid to the synthesis of these compounds, especially those that are longer than trimers. In the present study, syntheses of cinnamtannin A3 (epicatechin pentamer), A4 (epicatechin hexamer), catechin tetramer, pentamer, arecatannin A2 (epicatechin-epicatechin-epicatechin-catechin) and A3 (epicatechin-epicatechin-epicatechin-epicatechin-catechin) were achieved. The key reaction was a Lewis acid mediated equimolar condensation. The antitumor effects of these synthesized compounds against a human prostate cancer cell line (PC-3) were investigated. Among the tested compounds, cinnamtannin A3, A4 and arecatannin A3, which possess epicatechin oligomers longer than tetramers as the basic scaffold, showed significant activities for suppression of cell growth, invasion and FABP5 (fatty acid-binding protein 5) gene expression. Effects on cell cycle distribution showed that cell cycle arrest in the G2 phase was induced. Furthermore, these epicatechin oligomers suppressed significantly the expression of the cancer-promoting gene, FABP5, which is related to cell proliferation and metastasis in various cancer cells. Interestingly, the suppressive activities were associated with the degree of oligomerization of epicatechin. Thus, synthetic studies clearly demonstrate that epicatechin oligomers longer than trimers have significant anti-tumorigenic activities, but not the catechin counterparts. Nature Publishing Group UK 2017-08-10 /pmc/articles/PMC5552761/ /pubmed/28798415 http://dx.doi.org/10.1038/s41598-017-08059-x Text en © The Author(s) 2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Takanashi, Kohki Suda, Manato Matsumoto, Kiriko Ishihara, Chisato Toda, Kazuya Kawaguchi, Koichiro Senga, Shogo Kobayashi, Narumi Ichikawa, Mikihiro Katoh, Miyuki Hattori, Yasunao Kawahara, Sei-ichi Umezawa, Koji Fujii, Hiroshi Makabe, Hidefumi Epicatechin oligomers longer than trimers have anti-cancer activities, but not the catechin counterparts |
title | Epicatechin oligomers longer than trimers have anti-cancer activities, but not the catechin counterparts |
title_full | Epicatechin oligomers longer than trimers have anti-cancer activities, but not the catechin counterparts |
title_fullStr | Epicatechin oligomers longer than trimers have anti-cancer activities, but not the catechin counterparts |
title_full_unstemmed | Epicatechin oligomers longer than trimers have anti-cancer activities, but not the catechin counterparts |
title_short | Epicatechin oligomers longer than trimers have anti-cancer activities, but not the catechin counterparts |
title_sort | epicatechin oligomers longer than trimers have anti-cancer activities, but not the catechin counterparts |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5552761/ https://www.ncbi.nlm.nih.gov/pubmed/28798415 http://dx.doi.org/10.1038/s41598-017-08059-x |
work_keys_str_mv | AT takanashikohki epicatechinoligomerslongerthantrimershaveanticanceractivitiesbutnotthecatechincounterparts AT sudamanato epicatechinoligomerslongerthantrimershaveanticanceractivitiesbutnotthecatechincounterparts AT matsumotokiriko epicatechinoligomerslongerthantrimershaveanticanceractivitiesbutnotthecatechincounterparts AT ishiharachisato epicatechinoligomerslongerthantrimershaveanticanceractivitiesbutnotthecatechincounterparts AT todakazuya epicatechinoligomerslongerthantrimershaveanticanceractivitiesbutnotthecatechincounterparts AT kawaguchikoichiro epicatechinoligomerslongerthantrimershaveanticanceractivitiesbutnotthecatechincounterparts AT sengashogo epicatechinoligomerslongerthantrimershaveanticanceractivitiesbutnotthecatechincounterparts AT kobayashinarumi epicatechinoligomerslongerthantrimershaveanticanceractivitiesbutnotthecatechincounterparts AT ichikawamikihiro epicatechinoligomerslongerthantrimershaveanticanceractivitiesbutnotthecatechincounterparts AT katohmiyuki epicatechinoligomerslongerthantrimershaveanticanceractivitiesbutnotthecatechincounterparts AT hattoriyasunao epicatechinoligomerslongerthantrimershaveanticanceractivitiesbutnotthecatechincounterparts AT kawaharaseiichi epicatechinoligomerslongerthantrimershaveanticanceractivitiesbutnotthecatechincounterparts AT umezawakoji epicatechinoligomerslongerthantrimershaveanticanceractivitiesbutnotthecatechincounterparts AT fujiihiroshi epicatechinoligomerslongerthantrimershaveanticanceractivitiesbutnotthecatechincounterparts AT makabehidefumi epicatechinoligomerslongerthantrimershaveanticanceractivitiesbutnotthecatechincounterparts |